Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.
Paschalis NtoliosEleni ManoloudiArgyris TzouvelekisEvangelos BourosPachalis SteiropoulosStavros AnevlavisDemosthenes BourosMarios E FroudarakisPublished in: The clinical respiratory journal (2018)
Significant functional decline occurred at 24 months after first administration. The median survival and time to progression are in line with the published epidemiologic data. Further clinical trials complemented by mechanistic studies are sorely needed to delineate the role of ADSCs in IPF pathogenesis and treatment.
Keyphrases
- idiopathic pulmonary fibrosis
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- interstitial lung disease
- phase ii
- peritoneal dialysis
- bone marrow
- type diabetes
- prognostic factors
- systematic review
- randomized controlled trial
- metabolic syndrome
- electronic health record
- big data
- double blind
- cross sectional
- study protocol
- free survival
- replacement therapy
- deep learning
- adipose tissue
- systemic sclerosis
- case control